EP0457773A4 - N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists - Google Patents

N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists

Info

Publication number
EP0457773A4
EP0457773A4 EP19900902050 EP90902050A EP0457773A4 EP 0457773 A4 EP0457773 A4 EP 0457773A4 EP 19900902050 EP19900902050 EP 19900902050 EP 90902050 A EP90902050 A EP 90902050A EP 0457773 A4 EP0457773 A4 EP 0457773A4
Authority
EP
European Patent Office
Prior art keywords
compound
carbon atoms
group
phenyl
norbornyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900902050
Other languages
French (fr)
Other versions
EP0457773A1 (en
Inventor
Ray A. Olsson
Ted Marcus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitby Research Inc
Original Assignee
Whitby Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitby Research Inc filed Critical Whitby Research Inc
Publication of EP0457773A1 publication Critical patent/EP0457773A1/en
Publication of EP0457773A4 publication Critical patent/EP0457773A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Definitions

  • Novel compounds and a method of using them to antagonize adenosine receptors are provided wherein the compounds are represented by the general formula:
  • R ⁇ may be hydrogen or R 2
  • R 3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, thio, sufonate, sul- fonamide, sulfone, sulfoxamide, phenyl, alkyl-substituted amine, cycloalkyl-substituted amine, alkyl radicals having from 1 to 10 carbon atoms, and cycloalkyl radicals having
  • 4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms, wherein said alkyl group can be substituted with oxygen, for example ethers and alcohols.
  • 5 is selected from the group con ⁇ sisting of hydrogen; hydroxy; sulfonate; halogen; alkoxy and cycloalkoxy groups comprising 1 to 6 carbon atoms, wherein said alkoxy and cycloalkoxy groups can be substituted with phenyl; and amine, wherein said amine can be substituted with alkyl, cycloalkyl, or phenyl.
  • Adenosine receptors have been divided into two subtypes, based on adenylate cyclase activity: ⁇ _ (R ⁇ ) receptors mediate inhibition and 2 (R a ) receptors mediate stimulation of adenylate cyclase activity.
  • N 6 -substituted adeno ⁇ sine analogs like N 6 -R-phenyl isopropyl adenosine (R-PIA) have very high affinity for ⁇ _ adenosine receptors, but at A 2 receptors 5'-N-ethylcarboxamido-adenosine (NECA) is more potent than N 6 -substituted analogs .
  • NECA 5'-N-ethylcarboxamido-adenosine
  • Alkylxanthines such as caffeine and theophylline, are the best known antagonists at adenosine receptors.
  • Adenine was generally believed to have no effect on adenosine receptor-controlled systems. However, it was found that at low concentrations adenine displays specific competitive antagonism of adenosine-induced cyclic Amp accumulation in a human fibroblast cell line. Methylation of adenine at the 9-position increases potency about 4-fold in this assay. At higher concentration, both compounds show non-specific inhibitory activity.
  • R 2 is selected from the group consisting, of cyclo ⁇ alkyl radicals having from 3 to 8, preferably 3 to 7, ring carbon atoms, alkyl radicals having from 1 to 10 carbon atoms, aryl radicals having from 6 to 13, preferably 6 to 10, carbon atoms, aralkyl radicals having from 7 to 14, preferably 7 to ' 10, carbon atoms, and heteroatom- and halogen-substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of nitrogen, phosphorus, sulfur and oxygen; 1R ⁇ may be*hydrogen or R 2 , and R 3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, alkyl radicals having l to 10 carbon atoms, cycloalkyl radicals having from 3 to 8, preferably 5 to 6, ring carbon atoms, thio, sulfonate, sulfona ide, sulfon, sulfoxa ide, phenyl, alky
  • R4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms, wherein said alkyl group can be substituted with oxygen, for instance ethers and alcohols.
  • R 5 is selected from the group consist ⁇ ing of hydrogen; hydroxy; sulfonate; halogen; aljcoxy and cycloalkoxy groups comprising 1 to 6 carbon atoms, wherein said alkoxy and cycloalkoxy groups can be substituted with phenyl; and amine, wherein said amine can be substituted with phenyl and alkyl and cycloalkyl groups comprising 1 to 6 carbon atoms.
  • R ⁇ is hydrogen; wherein R 2 is endo-2-Norbornyl or cyclopentyl; wherein R 3 is bromine, chlorine, amino, hydrogen, thio, cyclopentyl or cyclopentylamine; wherein R4 is methyl, ethyl, 2-hydroxy- ethyl, phenyl, or 2-hydroxyethoxy methyl; and wherein R 5 is hydrogen, hydroxy or chlorine.
  • N 6 -(endo-2-Norbornyl)-8-Azido-9-MA 0.5g, 1.75 mmole
  • the solution in presence of 10% palladium on charcoal (lg) , was shaken with H 2 at 35 atm overnight. The suspension was filtered and evaporated to a small volume, and then poured through a C-18 column (HPLC) to give 0.36g 80% yield of N 6 -(endo-2- norbornyl)-8-Amino-9-MA.
  • N 6 (endo-2-Norbornyl)-9-Bromo-9-MA (0.15g, 0.62 mmole) in 12 ml acetic acid was added sodium acetate (0.5g) and 1.2 ml acetic anhydride. The mixture was allowed to reflux overnight. The mixture was then evaporated under vacuo and purified on a chromatotron using CHC1 3 , stepping to 2% ethanol, and finally to 4% ethanol on 2 mm plate giving 90 mg, 75% yield of N 6 -(endo-2-Norbornyl)-8-0xo-9-MA.
  • N 6 -(endo-2-Norbornyl)-8-Cyclopentylamine-9-MA To a solution of N 6 -(endo-2-Norbornyl)-8-Bromo-9-MA (0.5g, 1.55 mmols) in 20 ml ethanol was added 20ml of cyclopentylamine; the reaction mixture was refluxed overnight. The mixture was then evaporated under vacuo and passed through a C-18 column (HPLC) to.give 0.32g, 77% yield of N 6 -(endo-2-Norbornyl)-8-Cyclopentylamine-9-MA.
  • N 6 (endo-2-Norbornyl)2-Chloropurine was first prepared as follows: A mixture of 2,6-dichloropurine (5.0g, 26.45 mmoles) endo-2-aminobornane hydrochloride (5.0g, 33.86 mmoles) and triethyl amine (10 ml) in absolute ethanol was refluxed for 48 hours. The solution was then cooled to room temperature and evaporated in vacuo to a white solid. The white solid was washed with water and dried to yield 6.0g, 84% yield of N 6 -(endo-2-Norbornyl)2-Chloropurine used as is with no further purification for next step.
  • N 6 -(endo-2-Norbornyl)-8-bromo-9-MA (1.25g, 3.7 mmoles) and P0C1 3 was refluxed for 1 hour. Then the phosphorous oxychloride was removed in vacuo and the yellow solid was passed through a C-18 column (HPLC) to give 0.96g, 84% yield of N 6 -(endo-2-Norbornyl)-8-chloro-9-MA.
  • N 6 -substituted 9-methyladenines were assayed as adenosine antagonists in k ⁇ and A 2 test systems ( ⁇ kena, et al, FEBS Lett. 215(2), 203-208, 1987).
  • compounds were tested as inhibitors of the binding of N 6 -R-[ 3 H]-Phenylisopropyladenosine in rat brain membranes and for their ability to prevent R-PIA-induced inhibition of adenylate cyclase in rat fat cell membranes.
  • in vitro assays were conducted utilizing model tissues that are thought to contain homogenous populations of either the A ⁇ or A 2 adenosine receptors.
  • Four examples were characterized by their ability to antagonize competitively the action of adenosine agonists in eliciting two responses: the reduction in force of contraction of guinea pig atrium (A ⁇ ) ; and the decrease in the contractile tone of the guinea pig taenia caecum (A 2 ) .
  • the left atria from male guinea pigs were isolated, suspended between two punctate electrodes, and placed in a 20 ml organ bath that contained Krebs-Hensileit solution that was continuously gassed with 95% 0 2 + 5% C0 2 and maintained at 31°C. The resting tension was one gram. The atria were stimulated electrically at 1 Hz, 1 msec duration pulses at supramaximal voltage. The force of contraction was recorded isometrically.
  • Taenia from the guinea pig caecum were cut into lengths of 1.5-2 cm.
  • the tissues were suspended in a 20 ml organ bath containing de Jalon's solution that was gassed with 95% 0 2 + 5% C0 2 and maintained at 31 ⁇ C.
  • the resting tension was 1.5 g.
  • the contractile response was measured isotonically. Tissues were contracted with 10 M 5-methyl- furmethide and allowed sufficient time to reach a stable contraction before addition of adenosine agonists.
  • Sensitization is also observed when using high concentra ⁇ tions of 8-phenyltheophylline (8-PT) , a non-selective adenosine receptor antagonist. 8-PT did antagonize the effects of agonists at low concentrations. The lack of competitive antagonism by the other compounds suggests that the latter compounds do not interact appreciably with A 2 - adenosine receptors and are, thus, selective fbr A j adeno ⁇ sine receptors. * * * * * * * * * * * * * * *
  • N 6 -3-Pentyl-9-MA, N 6 -Cyclopentyl- -MA, N 6 - (endo-2-Norbornyl)-9-MA and N 6 -4-(2-thienyl)-3-butyl)-9-MA all were found to be competitive antagonists at adenosine receptors in the atria.
  • N 6 -3-Pentyl-9-MA and N 6 -l-(2- thienyl)-2-butyl-9-MA also produced increases in basal force of contraction in the atria.
  • Affinity constants (pK B ) for the present compounds determined using known methods are summarized in Table 2 below:
  • Rats were anesthetized with urethan and blood pressure was monitored via a carotid cannula. Drug injec ⁇ tions were made intravenously through a jugular cannula. Blood pressure, EGC, and heart rate were recorded on a Grass polygraph.
  • Adenosine produced a dose dependent decrease in blood pressure and heart rate, with a concom itant increase in the P-R interval of the ECG.
  • Administration of N 6 -(endo Norbornyl)-9-methyladenine attenuated the effects of subsequently administered adenosine on all parameters measured.
  • adenosine causes heart block; this effect was also substantially reduced by the agonist. Due to the short duration of action and direct route of ad ⁇ ministration of adenosine, it is often difficult to deter ⁇ mine whether adenosine decreased blood pressure by causing peripheral vasodilation or by reducing cardiac output.
  • NECA (5*-N-ethylcarboxamide adenosine) , which is longer-acting and selective for A 2 adenosine receptors, was used as an adenosine receptor agonist.
  • Prior administration of N-0861 attenuated the effects of NECA on the heart while minimally affecting the NECA-induced decrease in blood pressure.
  • N 6 -endo-2-Norbornyl) -9-methyladenine is a cardioselective adenosine receptor antagonist in vivo and support the data above showing selectively of the N-6 substituted 9-methyladenines of the invention as ⁇ adenosine receptor antagonists.
  • bovine brains were obtained fresh from a local slaughterhouse.
  • the caudate nuclei were dissected out and homogenized in Buffer A (50 mm Tris; 1 mm Na 2 -EDTA; 5 mm KCl; 1 mm MgCl 2 ; 2 mm CaCl 2 ; pH 7.4) using a Brinkman Polytron.
  • the homogenate was centri- fuged at 40,000 x g for 20 minutes and washed once.
  • the pellet was resuspended in Buffer A, incubated at 37°C for 15 minutes, then centrifuged.
  • the pellet was washed once more, resuspended to a protein concentration of 5-10 mg/ml in Buffer A and frozen at -70°C until use.
  • the A 2 assays also contained 50 nM cyclopentyl- adenosine to block the binding of [ 3 H]-NECA to K ⁇ receptors (Bruns et al, 1986) and 1 unit/ml adenosine deaminase to degrade endognous adenosines. Varying concentrations of test compounds were incubated with the appropriate * radio ⁇ ligand and membrane source for 1 hr at room temperature.
  • N 6 -substituted adenines are antagonists of A 2 - adenosine receptor-mediated stimulation of adenylate cyclase in A 2 -adenosine receptors and antagonists of A ⁇ -adenosine receptor-mediated inhibition of adenylate cyclase.
  • These compounds are useful in reversal of adenosine-mediated lipolysis, reversal of adenosine-mediated deleterious cardiovascular effects (conduction defects, hypotension) , reversal of adenosine-mediated vascular actions in kidney, bronchodilation, antiarrhythmic action, reversal of adeno- mediated relaxation of smooth muscle, anti-narcoleptic action, CNS stimulation, and blockade of adenosine mediated inhibition of neurotransmitter release.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A series of N6-substituted adenines are disclosed to be antagonists of A¿2?-adenosine receptor-mediated stimulation of adenylate cyclase in A2-adenosine receptors and antagonists of A1-adenosine receptor-mediated inhibition of adenylate cyclase. These compounds are useful in reversal of adenosine-mediated lipolysis, reversal of aenosine-mediated deleterious cardiovascular effects (conduction defects, hypotension), reversal of adenosine-mediated vascular actions in kidney, bronchodilation, antiarrhythmic action, reversal of adeno-mediated relaxation of smooth muscle, anti-narcoleptic action, CNS stimulation, and blockade of adenosine mediated inhibition of neurotransmitter release.

Description

N6-SUBSTITU ED 9-METHYLADENINES:
A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS
SUMMARY OF THE INVENTION
Novel compounds and a method of using them to antagonize adenosine receptors are provided wherein the compounds are represented by the general formula:
wherein 2 is selected from the group consisting of cyclo¬ alkyl radicals having from 3 to 8, preferably 3 to 7, ring carbon atoms, alkyl radicals having from 1 to 10 carbon atoms, aryl radicals having from 6 to 13, preferably 6 to 10, carbon atoms, aralkyl radicals having from 7 to 14, preferably 7 to 10, carbon atoms, and heteroatom- and halogen-substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of nitrogen, phosphorus, sulfur and oxygen; R^ may be hydrogen or R2, and R3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, thio, sufonate, sul- fonamide, sulfone, sulfoxamide, phenyl, alkyl-substituted amine, cycloalkyl-substituted amine, alkyl radicals having from 1 to 10 carbon atoms, and cycloalkyl radicals having from 3 to 8, preferably 5 to 6, ring carbon atoms. 4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms, wherein said alkyl group can be substituted with oxygen, for example ethers and alcohols. 5 is selected from the group con¬ sisting of hydrogen; hydroxy; sulfonate; halogen; alkoxy and cycloalkoxy groups comprising 1 to 6 carbon atoms, wherein said alkoxy and cycloalkoxy groups can be substituted with phenyl; and amine, wherein said amine can be substituted with alkyl, cycloalkyl, or phenyl.
BACKGROUND OF THE INVENTION This application is a continuation-in-part of U.S. patent application Serial No. 042,383, filed April 23, 1987 entitled "N6-Substituted 9-Methyladenines: A New Class of Adenosine Receptor Antagonists," which is incorporated herein by reference in its entirety.
Adenosine receptors have been divided into two subtypes, based on adenylate cyclase activity: τ_ (R^) receptors mediate inhibition and 2 (Ra) receptors mediate stimulation of adenylate cyclase activity. Some N6-substituted adeno¬ sine analogs, like N6-R-phenyl isopropyl adenosine (R-PIA) have very high affinity for ι_ adenosine receptors, but at A2 receptors 5'-N-ethylcarboxamido-adenosine (NECA) is more potent than N6-substituted analogs, Alkylxanthines, such as caffeine and theophylline, are the best known antagonists at adenosine receptors.
Adenine was generally believed to have no effect on adenosine receptor-controlled systems. However, it was found that at low concentrations adenine displays specific competitive antagonism of adenosine-induced cyclic Amp accumulation in a human fibroblast cell line. Methylation of adenine at the 9-position increases potency about 4-fold in this assay. At higher concentration, both compounds show non-specific inhibitory activity.
DETAILED DESCRIPTION OF THE INVENTION The compounds of this invention are represented by the general formula:
wherein R2 is selected from the group consisting, of cyclo¬ alkyl radicals having from 3 to 8, preferably 3 to 7, ring carbon atoms, alkyl radicals having from 1 to 10 carbon atoms, aryl radicals having from 6 to 13, preferably 6 to 10, carbon atoms, aralkyl radicals having from 7 to 14, preferably 7 to' 10, carbon atoms, and heteroatom- and halogen-substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of nitrogen, phosphorus, sulfur and oxygen; 1R^ may be*hydrogen or R2, and R3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, alkyl radicals having l to 10 carbon atoms, cycloalkyl radicals having from 3 to 8, preferably 5 to 6, ring carbon atoms, thio, sulfonate, sulfona ide, sulfon, sulfoxa ide, phenyl, alkyl-sύbstitued amine, and cycloalkyl substituted amine. R4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms, wherein said alkyl group can be substituted with oxygen, for instance ethers and alcohols. R5 is selected from the group consist¬ ing of hydrogen; hydroxy; sulfonate; halogen; aljcoxy and cycloalkoxy groups comprising 1 to 6 carbon atoms, wherein said alkoxy and cycloalkoxy groups can be substituted with phenyl; and amine, wherein said amine can be substituted with phenyl and alkyl and cycloalkyl groups comprising 1 to 6 carbon atoms.
The preferred compounds are those wherein R^ is hydrogen; wherein R2 is endo-2-Norbornyl or cyclopentyl; wherein R3 is bromine, chlorine, amino, hydrogen, thio, cyclopentyl or cyclopentylamine; wherein R4 is methyl, ethyl, 2-hydroxy- ethyl, phenyl, or 2-hydroxyethoxy methyl; and wherein R5 is hydrogen, hydroxy or chlorine.
The following is a list of compounds useful in the practice of the present invention. This list is intended to be illustrative and the scope of the invention is not limited to compounds named therein:
N6-Cyclobutyl-9-Methyl Adenine (MA)
N6-Cyclopentyl-9-MA
N6-Methylcyclopenty1-9-MA
N6-Cyclohexyl-9-MA
N6-Methyl-9-MA
N6-3-Pentyl-9-MA
N6-Phenyl-9-MA
N6-2-Fluorophenyl-9-MA
N6-Benzyl-9-MA
N6-2-Phenethyl-9-MA
N6-2-(3, ,5-Trimethoxyphenyl)ethyl-9-MA
N6-2-(3-Pyridylethyl)-9-MA
N6-2-(3-Thienylethyl)-9-MA
N6-E-l-Phenyl-2-propyl-9-MA
N6-S-l-Phenyl-2-propyl-9-MA
N6-(endo-2-Norbornyl)-9-MA
N6-l-(2-Thienyl)-2-butyl-9-MA N6-(exo-2-Norbornyl)-9-MA
N6-2,2-diphenylethyl-9-MA
N6-2-phenylethyl-9-MA
N6-2-(2-chlorophenyl)ethyl-9-MA
N6l-indanyl-9-MA
N6-2-aminoethyl-9-MA
N6-(N,N-Dimethylaminoethyl)-9-MA
N6-R-l-phenyl-l-ethyl-9-MA
N6-S-l-phenyl-l-ethyl-9-MA
N6-2-thienyl-9-MA
N6-(4-chloro-2-methyl phenyl)-9-MA
N6_ 2-(3-ethylindole)-9-MA
N<S- :i-methyl-2-phenylethyl)-9-MA N6_ [l-methyl-2-phenoxyethyl)-9-MA
N6-l-carboxy-l-butyl-9-MA
N6. endo-2-norbornyl)-2-σhloro-9-MA N<5- endo-2-norbornyl)-8-cyclopentyl-9-MA N6_ endo-2-norbornyl)-8-hydroxy-9-MA
N6- endo-2-norbornyl)-8-bromo-9-MA N6_ endo-2-norbornyl)-8-amino-9-MA
N6- endo-2-norbornyl)-8-carboxy-9-MA
N6-cyclopentyl-8-cyclopentyl-9-MA
N6_ endo-2-norbornyl)-9-[ (2-hydroxyethoxy)methyl]adenine N6_ endo-2-norbornyl)-8-thio-9-MA N6_ endo-2-norbornyl)-8-chloro-9-MA N6_ endo-2-norbornyl)-8-sulfonate-9-MA sodium salt N6_ endo-2-norbornyl)-2-hydroxy-9-MA
N6- endo-2-norbornyl)-8-cyclopentylamine-Sf-MA N6_ endo-2-norbornyl)-8-propylamine-9-MA
N6- endo-2-norbornyl)-9-phenyl adenine N6-cyclopentyl-2-chloro-9-MA N6-phenyl-2-chloro-9-MA N6-cyclopentyl-9-phenyl adenine N6-R-l-phenyl-2-propyl-9-phenyl adenine N6-S-l-phenyl-2-propyl-9-phenyl adenine
N6-[ (3-chloro-endo-2-norbornyl) ]-9-MA
N6-pheny1-9-phenyl adenine
2-ethoxy-9-MA
2-propoxy-9-MA
2-butoxy-9-MA
.2-isopropoxy-9-MA
2-(2-butoxy)-9-MA
2-(2-methyl propoxy) 9-MA
2-pentoxy-9-MA
2-(2-phenylethoxy) 9-MA
2-phenylamino-9-MA
9-hydroxyethyladenine
N6-cyclopenty1-9-benzyl adenine
N6-cyclohexyl-9-ethyl adenine
The preparation of 9-methyl adenines is well known. See R. K. Robins, K. J. Dille, and B. E. Christensen, J. Orσ. Chem.. 19, 930 (1954); R. K. Robins and H. H. Lin, J. Am. Chem. Soc.. 79, 490 (1957; and J. A. Montgomery and Carroll Temple, Jr., J. Am. Chem. Soc.. 79, 5238 (1957).
Preparation of N6-Cyclopentyl-9-Methyl Adenine
To prepare N6-cyclopentyl-9-methyl Adenine the following additional steps were taken. A mixture of 6- chloro-9-methyl Adenine (0.82g), cyclopentylamine (0.52 ml), triethylamine (0.53 ml) and ethanol (60 ml), was refluxed for 24 hours. The solution was concentrated in vacuo to a yellow syrup. The syrup was passed through a C-18 column to give 0.78g or 74% yield of with m.p. 108-109°C. 1HNMR- (Me2SO-d6): 5l-2(m,9 H) ; 3.7(S,CH3); 7.6(d,NH); 8.1(S,1H); 8.2(S,1H) .
Preparation of N6-3-Pentyl-9-Methyladenine A mixture of 6-chloro-9-methyladenine (1.5g), 3-pen- tylamine (1.3 ml), triethylamine (1.3ml) and ethanol (60 ml) , was refluxed for 24 hours. The solution was con¬ centrated and passed through a C-18 column to give a white solid having .p. 107-109βC.
Preparation of N6-(2-Aminonorbornyl)-9-methyl Adenine
A mixture of 1.5g 6-chloro-9-methyl Adenine, 1-75 g endo- 2-aminonor-bornane, 2.9 ml triethylamine and 60 *ml ethanol was refluxed overnight. The solution was then concentrated in vacuo and the remainder was passed through C-18 prep- chromatography to give 1.6g (75% yield) m.p. 130-f131°C. 1HNMR(Me2S0-d6) : 51-2.6(m,10 H) ; 3.8(S, CH3) ; 4.1(m,lH); 7.2(S,NH); 7.4(8,1H); 7.6(8,1H).
Preparation of N6-(endo-2-Norbornyl)-8-Bromo-9-MA *
To a stirred suspension of N6-(endo-2-norbornyl)-9-MA (6g, 24.66 mmoles) in 150 ml of 1M sodium acetate buffer (pH 3.9) was added a solution of bromine (3.0 ml) in 300 ml of 1M sodium acetate buffer (pH 3.9). The mixture was stirred overnight and the resulting precipitate was filtered and washed with water. To the residue was added silica gel and the suspension was evaporated to a powder. The powder was added to a silica gel column (150g, packed with petroleum ether) . The purine was eluted with 10% to 25% ethylacetate in petroleum ether. Evaporation of the" appropriate fractions gave 6.7g, 84% yield of N6-(endo-2-Norbornyl)-8- Bromo-9-MA.
Preparation of N6-(endo-2-Norbornyl)-8-Azido-9-MA
To a solution of N6-(endo-2-Norbornyl)-9-Bromo-9-MA (0.72g, 2.23 mmoles) in DMF was added sodium azide (0.91g, 13.98 mmoles). The mixture was heated at 70-80°C overnight. The crude was dissolved in water, extracted with ethyl acetate, and then dried over magnesium sulfate and the organic phase was evaporated in vacuo to give 0.62g, 98% yield.
Preparation of N6-(endo-2-Norbornyl)-8-Amino-9-MA
The crude product, N6-(endo-2-Norbornyl)-8-Azido-9-MA (0.5g, 1.75 mmole) was dissolved in ethanol. The solution, in presence of 10% palladium on charcoal (lg) , was shaken with H2 at 35 atm overnight. The suspension was filtered and evaporated to a small volume, and then poured through a C-18 column (HPLC) to give 0.36g 80% yield of N6-(endo-2- norbornyl)-8-Amino-9-MA.
Preparation of N6-(endo-2-Norbornyl)-8-0xo-9-MA
To a mixture of N6(endo-2-Norbornyl)-9-Bromo-9-MA (0.15g, 0.62 mmole) in 12 ml acetic acid was added sodium acetate (0.5g) and 1.2 ml acetic anhydride. The mixture was allowed to reflux overnight. The mixture was then evaporated under vacuo and purified on a chromatotron using CHC13, stepping to 2% ethanol, and finally to 4% ethanol on 2 mm plate giving 90 mg, 75% yield of N6-(endo-2-Norbornyl)-8-0xo-9-MA.
Preparation of N6-(endo-2-Norbornyl)-8-Cyclopentylamine-9-MA To a solution of N6-(endo-2-Norbornyl)-8-Bromo-9-MA (0.5g, 1.55 mmols) in 20 ml ethanol was added 20ml of cyclopentylamine; the reaction mixture was refluxed overnight. The mixture was then evaporated under vacuo and passed through a C-18 column (HPLC) to.give 0.32g, 77% yield of N6-(endo-2-Norbornyl)-8-Cyclopentylamine-9-MA.
Preparation of N6-(endo-2-Norbornyl)8-Bromo-2-Chloro-9-MA
N6(endo-2-Norbornyl)2-Chloropurine was first prepared as follows: A mixture of 2,6-dichloropurine (5.0g, 26.45 mmoles) endo-2-aminobornane hydrochloride (5.0g, 33.86 mmoles) and triethyl amine (10 ml) in absolute ethanol was refluxed for 48 hours. The solution was then cooled to room temperature and evaporated in vacuo to a white solid. The white solid was washed with water and dried to yield 6.0g, 84% yield of N6-(endo-2-Norbornyl)2-Chloropurine used as is with no further purification for next step.
A mixture of N6-(endo-2-Norbornyl)-2-chloropurine (5.0g, 18.96 mmoles), triethyl ammonium hydroxide (18.9 ml), and methyl iodide (1.41 ml, 22.68 mmoles) in dichloromethane was heated to 35°C for 24 hours. The solution was then evaporated in vacuo and the syrup was crystallized in methanol to give 4.0g, 76% yield of N6-(endo-2-Norbornyl)2- chloro-9-MA.
To a stirred solution of N6-(endo-2-Norbornyl)-2-chloro- 9-MA (4.3g, 14.4 mmoles) in acetate buffer (l molar acetic acid and 1 M sodium acetate mixture, 45:1 ratio respectively; pH ≡ 3.9) was added dropwise Bromine (3.12g, 19.56 mmoles) dissolved in the acetate buffer. The reaction mixture was stirred for 72 hours; the mixture was then filtered and the solid material collected was eluted from ethyl acetate/petroleum ether on silica gel column to yield 4.9g, 85% of N6-(endo-2-Norbornyl)8-Bromo-2-Chloro-9-MA.
Preparation of N6-(endo-2-Norbornyl)-8-Cyclopentyl-9-MA
To a vigorously stirred solution of 2g (12.2 mmoles) of 4-methylamino-5-amino-6-chloropyrimidine in CHC13 was added dropwise over a period of 20 minutes cyclopentane carbonyl chloride (1.6g, 12.2 mmoles). The mixture was stirred overnight and then evaporated in vacuo to a yellow syrup. The syrup was then dissolved in methanol and purified through a C-18 column (HPLC) to give 2.2g, 71% yield of 4 methylamino-6-chloro-5-cyclopentylamido-pyrimidine. 4-methylamino-6-chloro-5-cyclopentylamido-pyrimidine 2.2g, 8.6 mmoles) was refluxed in POCl3 for approximately 2 hours. The solution was concentrated in vacuo to a syrup. The syrup was added dropwise to ice. The aqueous mixture was then extracted with chloroform. The organic layer was evaporated and the syrup was passed through a C-18 column (HPLC) giving 1.25g, 63% yield of 8-cyclopentyl-6-chloro-9- methyladenine.
A mixture of 8-cyclopentyl-6-chloro-9-methyladenine (0.48g 2.0 mmoles) and endo-2-aminonorbornane hydrochloride (0.5g, 3.4 mmoles) in absolute ethanol was refluxed for 48 hours. The mixture was then evaporated in vacuo and purified through a C-18 column (HPLC) to give 0.45g, 71% yield of N6-(endo-2-Norbornyl)-8-cyclopentyl-9-MA.
Preparation of N6-(endo-2-Norbornyl)-8-Chloro-9-MA
A mixture of N6-(endo-2-Norbornyl)-8-bromo-9-MA (1.25g, 3.7 mmoles) and P0C13 was refluxed for 1 hour. Then the phosphorous oxychloride was removed in vacuo and the yellow solid was passed through a C-18 column (HPLC) to give 0.96g, 84% yield of N6-(endo-2-Norbornyl)-8-chloro-9-MA.
Preparation of N6-(endo-2-Norbornyl)-9-[(2-hydroxyethoxy) methyl]purine.
To a solution of 6-chloropurine (6g, 38.8 mmoles) in DMF was added sodium hydride 60% (0.93g) over 1.5 hour period. (2-acetoxyethoxy) ethyl bromide was then added at room temperature; the reaction mixture was allowed to stir for 2 hours under N2 atmosphere. H20 was added and the product was extracted with ethyl acetate. The organic phase was dried over MgS04, filtered, and evaporated in vacuo to give a light yellow solid 7.1g, 68% yield of 9-[(2-Acetoxy- ethoxy)methyl]-6-chloro-purine. The crude wa^used without further purification.
To a solution of 9-[ (2-acetoxyethoxy)methyl]-6-chloro- purine (5.1g, 18.8 mmoles) in ethanol and triethylamine was added endo-2-aminonorbornane hydrochloride (4.0g*, 27.1 mmoles) . The mixture was refluxed in vacuo and the residue was purified by HPLC to give 4.70g, 77% yield of N6-(endo-2- Norbornyl)-9-[ (2-acetoxyethoxy)methyl]purine.
A solution of N6-(endo-2-Norbornyl)-9-[ (2-acetoxyethoxy) methyl]purine (3.75g, 10.8 mmoles) in methanol was saturated with NH3 gas under N2. The mixture was stirred overnight, then evaporated in vacuo to give 2.03g, 62% yield o__ N6-(endo-2-Norbornyl)-9-[ (2-hydroxyethoxy) ethyl]purine.
The invention is further illustrated by the follow¬ ing examples which are illustrative of various aspects of the invention. These examples are not intended as limiting the scope of the invention as defined by the appended claims.
PHARMACOLOGIC TESTING
A series of N6-substituted 9-methyladenines were assayed as adenosine antagonists in k^ and A2 test systems (ϋkena, et al, FEBS Lett. 215(2), 203-208, 1987). For activity at &1 receptors, compounds were tested as inhibitors of the binding of N6-R-[3H]-Phenylisopropyladenosine in rat brain membranes and for their ability to prevent R-PIA-induced inhibition of adenylate cyclase in rat fat cell membranes. For activity at A2 receptors, compounds were tested as antagonists of NECA-stimulated adenylate cyclase in membranes of human platelets and rat PC12 cells. It is known that &ι_ receptors influence inhibition of adenylate cyclase in fat, brain and heart cells; whereas A2 receptors stimulate adenylate cyclase in endothelial and smooth muscle cells. (See John W. Daly, et al., "Structure- Activity Relationship for N6-Substituted Adenosines at a Brain A^Adenosine Receptor With A Comparison to an A2- Adenosine Receptor Regulating Coronary Blood Flow," Bio¬ chemical Pharmacology. Vol. 35. No. 15, pp. 2467-2471 (1986)) .
The results summarized below in Table I show that N6 substitution can markedly increase the potency of 9- methyladenine at adenosine receptors. The lower apparent affinity values (Kg, K^) identify the most potent compounds. The most pronounced effect is seen at ^ receptors. For example, N6-Cyclopentyl-9-methyladenine is at least 100-fold more potent than 9-methyladenine at A^ receptors. At A2 receptors, this compound is 5-fold more potent than 9- methyladenine in the human platelet assay. Thus, this data demonstrates the activity of a novel series of adenosine antagonists.
TABLE 1
Effec s Effects
I nd-H) VS NECA St imulat ion KB( M)
(Adenyl ate Cyc lase) vs PIA INHIBITION (Adenylate Cyclase)
1 Adenine 760 570 > 1000
2 9 - Me t hy I aden i ne (9-MA) 24 24 112
«-• ubst i tuted 9 - me t h y I aden i nes
3. N6-Cyc lobutyl -0-HA 5.5 23 0.89
4. M6-Cyclopentyl -9-MA 4.9 25 1.3
5. N6-Methylcylopentyt -9-MΛ 45 56 9.0 6. Cyclohexyl -9-MA 7.4 21 0.65 7. N°-Hethyl -9-MA 150 130 220 8. 3 - Pen ty I - 9-HA 11 53 7.6 9. Mβ- Pheny I - 9 - MA 21 107 10
10. N6-2- uorophenyl -9-HΛ 11 29 17 11. N6- 2 - Benzyl -9-MA 57 100 49 12. M6- 2-Phenethy I -9-MA 170 120 >300 13. N6- 2 - ( 3 ,4 , 5- Tr i m- ethoxyphenylethyl ) -9-MA 23 40 122
14 M6-2-(3-Pyridylethyl )-9-MA 92 117 96 15 M -2- (3-Thi enyl ethyl ) -9-HA 14 25 24
16 N6-R- 1 -Phenyl -2-propyl -9-MA 13 25 7.2 17 M6-S- 1 -Phenyl -2-propyl -9-MA 23 74 23
(A) - Human P latelet Membranes
(B) - Rat PC12 Membranes
(C) - Rat Fat Cel l Membranes
(D) - Rat Brain Membranes
FURTHER FUNCTIONAL ASSAYS
To test the selectivity of the compounds of the invention, in vitro assays were conducted utilizing model tissues that are thought to contain homogenous populations of either the A^ or A2 adenosine receptors. Four examples were characterized by their ability to antagonize competitively the action of adenosine agonists in eliciting two responses: the reduction in force of contraction of guinea pig atrium (A^) ; and the decrease in the contractile tone of the guinea pig taenia caecum (A2) .
The left atria from male guinea pigs were isolated, suspended between two punctate electrodes, and placed in a 20 ml organ bath that contained Krebs-Hensileit solution that was continuously gassed with 95% 02 + 5% C02 and maintained at 31°C. The resting tension was one gram. The atria were stimulated electrically at 1 Hz, 1 msec duration pulses at supramaximal voltage. The force of contraction was recorded isometrically.
Taenia from the guinea pig caecum were cut into lengths of 1.5-2 cm. The tissues were suspended in a 20 ml organ bath containing de Jalon's solution that was gassed with 95% 02 + 5% C02 and maintained at 31βC. The resting tension was 1.5 g. The contractile response was measured isotonically. Tissues were contracted with 10 M 5-methyl- furmethide and allowed sufficient time to reach a stable contraction before addition of adenosine agonists.
The ability of the compounds to antagonize the effects of agonists was analyzed using modified Schild plots. Although there was some sensitization of the tissue, i.e. addition of the agonist produced a larger response in the presence of high concentrations of the subject com¬ pounds, N6-3-Pentyl-9-MA, N6-Cyclopentyl-9-MA and N6-(endo- 2-Norbornyl)-9-MA did not competitively antagonize" the effects of adenosine agonists in relaxing the taenia caecum. Sensitization is also observed when using high concentra¬ tions of 8-phenyltheophylline (8-PT) , a non-selective adenosine receptor antagonist. 8-PT did antagonize the effects of agonists at low concentrations. The lack of competitive antagonism by the other compounds suggests that the latter compounds do not interact appreciably with A2- adenosine receptors and are, thus, selective fbr Aj adeno¬ sine receptors. * *
However, N6-3-Pentyl-9-MA, N6-Cyclopentyl- -MA, N6- (endo-2-Norbornyl)-9-MA and N6-4-(2-thienyl)-3-butyl)-9-MA all were found to be competitive antagonists at adenosine receptors in the atria. N6-3-Pentyl-9-MA and N6-l-(2- thienyl)-2-butyl-9-MA also produced increases in basal force of contraction in the atria. Affinity constants (pKB) for the present compounds determined using known methods are summarized in Table 2 below:
Table 2 Druσ pKB
N6-3-Pentyl-9-MA 5.4 ± 0.14
N6-Cyclopentyl-9-MA 6.17 ± 0.11
N6-(endo-2-Norbornyl)-9-MA 6.28 ± 0.09
N6-l-(2-Thienyl)-2-butyl)-9-MA 5.36 ± 0.1
These results show that the above examples display selectivity towards the A adenosine receptor, with N6- (endo-2-Norbornyl)-9-MA being the most potent antagonist. IN VIVO ASSAY
In vitro selectivity of the present antagonists was confirmed by in vivo tests on rat heart rate and blood pressure, the former associated with -^ receptors and the latter associated with A2 receptors.
Rats were anesthetized with urethan and blood pressure was monitored via a carotid cannula. Drug injec¬ tions were made intravenously through a jugular cannula. Blood pressure, EGC, and heart rate were recorded on a Grass polygraph.
Adenosine produced a dose dependent decrease in blood pressure and heart rate, with a concom itant increase in the P-R interval of the ECG. Administration of N6-(endo Norbornyl)-9-methyladenine attenuated the effects of subsequently administered adenosine on all parameters measured. At high doses, adenosine causes heart block; this effect was also substantially reduced by the agonist. Due to the short duration of action and direct route of ad¬ ministration of adenosine, it is often difficult to deter¬ mine whether adenosine decreased blood pressure by causing peripheral vasodilation or by reducing cardiac output. To overcome these problems, NECA (5*-N-ethylcarboxamide adenosine) , which is longer-acting and selective for A2 adenosine receptors, was used as an adenosine receptor agonist. Prior administration of N-0861 attenuated the effects of NECA on the heart while minimally affecting the NECA-induced decrease in blood pressure. These results show that N6-endo-2-Norbornyl) -9-methyladenine is a cardioselective adenosine receptor antagonist in vivo and support the data above showing selectively of the N-6 substituted 9-methyladenines of the invention as ^ adenosine receptor antagonists. FURTHER RECEPTOR AFFINITY ASSAYS
Further tests to discover the affinities of test compounds at A2 receptors were conducted. [3H]-N-ethylcar- boxamido adenosine ([3H-]-NECA) was used as the radioligand, bovine caudate was the source of membranes, and the assay buffer was 50 mM Tris; 10 mM MgCl2, pH 7.4.
To provide bovine caudate nuclei, bovine brains were obtained fresh from a local slaughterhouse. The caudate nuclei were dissected out and homogenized in Buffer A (50 mm Tris; 1 mm Na2-EDTA; 5 mm KCl; 1 mm MgCl2; 2 mm CaCl2; pH 7.4) using a Brinkman Polytron. The homogenate was centri- fuged at 40,000 x g for 20 minutes and washed once. The pellet was resuspended in Buffer A, incubated at 37°C for 15 minutes, then centrifuged. The pellet was washed once more, resuspended to a protein concentration of 5-10 mg/ml in Buffer A and frozen at -70°C until use.
The A2 assays also contained 50 nM cyclopentyl- adenosine to block the binding of [3H]-NECA to K^ receptors (Bruns et al, 1986) and 1 unit/ml adenosine deaminase to degrade endognous adenosines. Varying concentrations of test compounds were incubated with the appropriate* radio¬ ligand and membrane source for 1 hr at room temperature.
Assays were terminated by filtration over Whatman GF/B filters that had been pre-soaked with 0.1% polyethyl- eneimine using a 24 port Brandell cell hawester. The filters were washed three times with 3 ml of ice cold"buffer and transfered to plastic scintillation vials to which 4 ml of Beckman Ready-Protein scintillation cocktail was added. The tubes were shaken and counted in a Beckman 3801 scintil¬ lation counter that converted cpm to dpm. •Data were analyzed by utilizing the Ligand® commercial computer program (Munson and Rodbard, 1980) .
The results of these tests, expressed as the molar concentration of test compound needed to displace 50 percent of the [3H]-CHA radioligand from rat cortical A.^ receptors, are summarized in Table 3 below:
Table 3 Adenosine Antagonists
Rat Cortical
Sample Binding Constant No. Name Ki (M)
0861 N6-(endo-2-norbornyl)-9-MA 11.6 x 10~8
0913 N6-(endo-2-norbornyl)-2-chloro-9-MA 10.5 X 10"8
0966 N6-2 , 2-diphenylethyl-9-MA >10"5
0967 N6-2 (2-chlorophenylethyl) 9-MA >10"5
0982 N6-2-Aminoethyl-9-MA >10"5
0983 N6-(2 ,2-N-dimethylethyl)-9-MA >10"5 0840 N6-cyclopentyl-9-MA 37.5 x 10~8
0984 N6-R-l-phenyl-l-ethyl-9-MA >10~5
0985 N6-S-l-phenyl-l-ethyl-9-MA >10"4
0986 N6-S-l-phenyl-2-propyl-9-MA >10~5
0987 N6 2-thienyl-9-MA >10"4
0988 N6(4-chloro-2-methylphenyl)-9-MA >10~5
0989 N6-2-(3-ethylindole)-9-MA >10"5
0990 N6-2-(phenethyl)9-MA >10"5
1001 N6-(endo-2-norbornyl)-8-oxo-9-MA «10"5
1002 N6-2-(3,4,5-trimethoxyphenyl)ethyl-9-MA >10"5
1003 N6-(endo-2-norbornyl)-8-bromo-9-MA 1.3 X 10~8
1004 N6-l-carboxy-l-butyl-9-MA >10-4
1005 N6-(endo-2-norbornyl)-8-amino-9-MA 87 X 10~8
1006 N6-(endo-2-norbornyl)-8-carboxy-9-MA
Sodium Salt >10 -5 1059 N6-(endo-2-norbornyl)9-[ (2 hydroxyethoxy) methyl]adenine 49 x 10 -8
1060 N6-(endo-2-norbornyl)-8-thio-9-MA 37 x 10 -8 1061 N6-(endo-2-norbornyl)-8-chloro-9-MA 1.5 X 10 -8 1062 N6-(endo-2-norbornyl)-8-sulfonate- 9-MA Sodium Salt >10 -4
1063 N6-(Endo-2-norbornyl)-2-oxo-9-MA 112 X 10 -8 1064 N^-(endo-2-norbornyl)-8-cyclopentyl- amine-9-MA 190 X 10 -8
0964 N6-(endo-2-norbornyl)-8-cyclopentyl-9-MA 24 x 10"*8 0965 N6-cyclopentyl-8-cyclopentyl-9-MA 14.1 x 10 -8 0978 N6-(exo-2-norbornyl)-9-MA 43* x 10"8
The compounds in Table 3 for which a solution having a concentration greater than 10~5M was required to displace 50 percent of the radioligand are deemed ineffective as A^ adenosine receptor antagonists.
In further experiments designed to determine the selectivity of N6-endo-2-Norbornyl-9-methyl adenine at A._ receptors, [3H]-cyclohexyladenosine ([3H]-CHA) was used as the radioligand, rat cortical membranes were the receptor source, and the assay buffer was 50 mM Tris; 2 mM MgCl2 pH 7.4.
Male Sprague Dawley rats were killed by decapitation and the brains removed. The cerebral cortices were homogenized in 50 mm Tris; 2mm MgCl (pH 7.4), and centrifuged at 40,000 x g for 10 minutes. The pellet was washed once, resuspended in Tris/MgCl2 and incubated with 8 units/ml adenosine deaminase at 37°C for 30 minutes. The homogenate was centrifuged, washed once, resuspended to . a protein concentration of 5-10 mg/ml and frozen at -70°C until use. The results in Table 4 below show that the test compound has 170 times more affinity for &.χ receptors than for A2 recep¬ tors.
Table 4
Selectivity of N6-endo-2-Norbornyl-9-MA Bovine Caudate Binding Constants At Ai Receptors At A2 Receptors
EilMl 4.1 X 10~8M
References
Munson, Peter J. and Rodbard, David (1980) . "Ligand: A Versatile Computerized Approach for Characterizing Ligand- Binding Systems." Anal. Biochem. 107:220-239.
Bruns, Robert F. , Lee, Gina H. , and Pugsley, Thomas A. (1986) "Characterization of the A Adenosine Receptor Labeled by 3H-NeCA in Rat Striatal Membranes," Mol. Pharmacol. 29:331-346.
These N6-substituted adenines are antagonists of A2- adenosine receptor-mediated stimulation of adenylate cyclase in A2-adenosine receptors and antagonists of A^-adenosine receptor-mediated inhibition of adenylate cyclase. These compounds are useful in reversal of adenosine-mediated lipolysis, reversal of adenosine-mediated deleterious cardiovascular effects (conduction defects, hypotension) , reversal of adenosine-mediated vascular actions in kidney, bronchodilation, antiarrhythmic action, reversal of adeno- mediated relaxation of smooth muscle, anti-narcoleptic action, CNS stimulation, and blockade of adenosine mediated inhibition of neurotransmitter release.
While particular embodiments of the invention have been described it will be understood of course that the invention is not limited thereto since many obvious modifications can be made and it is intended to include within this invention any such modifications as will fall within the scope of the appended claims.

Claims

What is claimed is:
1. Novel compounds represented by the general formula:
wherein R2 is selected from the group consisting of cycloalkyl radicals having from 3 to 8 ring carbon atoms, alkyl radicals having from 1 to 10 carbon atoms, aryl radicals having from 6 to 13 carbon atoms, aralkyl radicals having from 7 to 14 carbon atoms and halogen- and heteroatom-substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of halogen, nitrogen, phosphorus," sulfur and oxygen; R may be hydrogen or R2, and R3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, thio, sufonate, sulfonamide, sulfone, sulfoxamide, phenyl, alkyl- or cycloalkyl-substituted amine, alkyl radicals having 1 to 10 carbon atoms and cycloalkyl radicals having from 3 to 8 ring carbon atoms. R4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms wherein said alkyl group can be substituted with oxygen; and R5 is selected from the group consisting of hydrogen, hydroxy, halogen, alkoxy and cycloalkoxy groups comprising 1 to 6 carbon atoms, wherein said alkoxy and cycloalkoxy groups can be substituted with phenyl; and amine wherein said amine can be substituted with members of the group consisting of phenyl, and alkyl and cycloalkyl, having 1 to 6 carbon atoms.
2. The compound of claim 1 wherein R4 is methyl. 3. The compound of claim 2 wherein R^ is hydrogen.
4. The compound of claim 3 wherein R2 is a cycloalkyl having from 4 to 8 carbon atoms in the ring. r
5. The compound of claim 3 wherein R2 is phenyl or a substituted phenyl.
6. The compound of claim 3 wherein R2 is 2-norbornyl, cyclopentyl and R3 is selected from the group consisting of hydrogen, cyclopentyl, oxo, bromo, amino, carboxy, thio, chloro, fluoro, sulfonate, sulfona ido, cyclopentyϊamino, cyclopentyl, and physiologically acceptable salts thereof.
7. The compound of claim 3 wherein R2 is selected from the group consisting of benzyl, phenyl, o-flύorophenyl, 3,4,5-trimethoxyphenylethyl, 3-pentyl, 2-phenylethyl, 2-(2- chlorophenylethyl) ; 1-indanyl, 2-aminoethyl, N,N-dimethyl- aminoethyl, 2-thienylbutyl, and cyclohexyl.
8. The compound of claim 3 wherein R2 is endo-2- Norbornyl and R4 is phenyl or (2-hydroxyethoxy)methyl.
9. The compound of claim 1 selected from the group consisting of N6-(endo-2-Norbornyl)-9-[ (2-hydroxyethoxy) methyl]adenine, N6-(endo-2-Norbornyl) -8-thio-9-methyl adenine, N6-(endo-2-Norbornyl)-8-chloro-9-methyl adenine, N6-(endo-2-Norbornyl)-2-oxo-9-methyl adenine, N6-(endo-2- Norbornyl)-8-cyclopentylamino-9-methyl adenine, N6-cyclo- pentyl-9-methyl adenine, N6-(endo-2-Norbornyl)-9-methyl adenine, N6-(endo-2-norbornyl)-8-bromo-9-MA, N6-cycϊopentyl- 8-cyclopentyl-9-methyl adenine, N6-(exo-2-norb rnyl)-9-MA, N6-cyclopentyl-2-chloro-9-methyl adenine, N6-[(3-chloro)- endo-2-norbornyl]-9-MA, N6-cyclopentyl-9-phenyl adenine, N6- (endo-2-norbornyl)-8-cyclopentyl-9-MA, N6-cyclopentyl-9- benzyl adenine, and N6-(endo-2-norbornyl)-8-amino-9-MA.
10. The compound of claim 2 wherein R5 is selected from the group consisting of hydrogen, ethoxy, methoxy, propoxy, n-butoxy, isopropoxy, 1-methylpropoxy, 2-methylpropoxy, 2- phenyl-ethoxy, methylamino, butylamino and anilino.
11. The compound of claim 3 wherein R5 is chloro.
12. The compound of claim 3 wherein R2 is selected from the group consisting of 3-pentyl, l-phenyl-2-propyl, and phenyl.
13. The compound of claim 2 wherein R2 is hydrogen and R5 is selected from the group consisting of ethoxy, methoxy, propoxy, n-butoxy, isopropoxy, butyl-2-oxy, 2-methylpropoxy, pentoxy, 2-phenylethoxy, methylamino, butylamino and anilino.
14. The compound of claim 11 wherein R2 is 2-(3- thienylethyl) .
15. The compound of claim 7 wherein R2 is cyclohexyl.
16. The compound of claim 11 wherein R2 is 2-(3- pyridylethyl) .
17. The method of antagonizing the A2-adenosine receptor-mediated stimulation of adenylate cyclase which comprises administering to a subject an effective amount of one or more of the compounds of claim 4, 6, 7, 8 or 9. 18. The method of claim 17 wherein said subject is a human.
19. The method of antagonizing the A -adenosine receptor-mediated inhibition of adenylate cyclase which comprises administering to a subject an effective amount of a compound of claim 4, 6, 7, 8 or 9.
20. The method of claim 19 wherein said subject is a human.
21. The method of antagonizing the adenosine receptor which comprises administering to a subject an effective amount of a compound selected from the group of compounds represented by the general formula
wherein R2 ^s selected from the group consisting of cycloalkyl radicals having from 3 to 8 ring carbon atoms, alkyl radicals having from 1 to 10 carbon atoms, aryl radicals having from 6 to 13 carbon atoms, aralkyl radicals having from 7 to 14 carbon atoms, and halogen- and heteroatom-substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of halogen, nitrogen, phosphorus, sulfur and oxygen; R^ may be hydrogen or R , and R3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, thio, sufonate, sulfonamide, sulfone, sulfoxamide phenyl, alkyl- or cycloalkyl-substituted amine, alkyl radicals having 1 to 10 carbon atoms and cycloalkyl radicals having from 3 to 8 ring carbon atoms. R4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms wherein said alkyl group can be substituted with oxygen; and R5 is selected from the group consisting of hydrogen, hydroxy, amine, halogen, alkoxy and cycloakoxy groups comprising 1 to 6 carbon atoms, wherein said alkoxy and cycloalkoxy groups can be substituted with phenyl; and amine, wherein said amine can be substituted with members of the group consisting of phenyl, alkyl, cycloalkyl, having 1 to 6 carbon atoms.
22. The method of claim 21 wherein said subject is a human.
23. Novel compounds represented by the general formula:
wherein R^ is selected from the group consisting of cycloalkyl radicals having from 3 to 7 ring carbon atoms, alkyl radicals having from 2 to 10 carbon atoms, aryl radicals having from 6 to 10 carbon atoms, aralkyl radicals having from 7 to 10 carbon atoms and heteroatom substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of halogen, nitrogen, phosphorus, sulfur and oxygen; R may be hydrogen or Rlf and R3 is an alkyl group comprising from l to 4 carbon atoms. 24. The compound of claim 23 wherein R3 is methyl.
25. The compound of claim 24 wherein R2 is hydrogen.
26. The compound of claim 25 wherein R is a cycloalkyl having from 4 to 6 carbon atoms in the ring.
27. The compound of claim 25 wherein R is phenyl or a substituted phenyl.
28. The compound of claim 27 wherein R^ is selected from the group consisting of phenyl, o-fluorophenyl and 3,4,5- trimethoxyphenyl.
29. The compound of claim 25 wherein R is benzyl or 2- phenylethyl.
30. The compound of claim 25 wherein ^ is 2-(3- pyridylethyl) or 2-(3-thienylethyl) .
31. The compound of claim 25 wherein R is 3-pentyl.
32. The compound of claim 24 wherein R2 is selected from the group consisting of methyl and 2-propyl and ^ is selected from the group consisting of cyclopentyl and phenyl.
33. The compound of claim 30 wherein R^ is 2-(3- thienylethyl) .
34. The compound of claim 32 wherein R2 is 2-propyl and i is phenyl.
35. The compound of claim 28 wherein R^ is benzyl. 36. The compound of claim 30 wherein R is 2-(3- pyridylethyl) .
37. The method of antagonizing the A2-adenosine receptor-mediated stimulation of adenylate cyclase which comprises administering to a subject an effective amount of one or more of the compounds of claims 26, 28, 31, 33 or 34.
38. The method of claim 37 wherein said subject is a human.
39. The method of antagonizing the Ai-adenosine receptor-mediated inhibition of adenylate cyclase which comprises administering to a subject an effective amount of a compound of claim 26, 28, 31, 33, 34, 35 or 36.
40. The method of claim 39 wherein said subject is a human.
41. The method of antagonizing the adenosine receptor which comprises administering to a subject an effective amount of a compound selected from the group of compounds represented by the general formula
wherein ^ is selected from the group consisting of cycloalkyl radicals having from 3 to 7 ring carbon atoms, alkyl .radicals having from 1 to 10 carbon atoms, aryl radicals having from 6 to 10 carbon atoms, aralkyl radicals having from 7 to 10 carbon atoms and heteroatom substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of halogen, nitrogen, phosphorus, sulfur and oxygen; R2 may be hydrogen or R, and R3 is an alkyl group comprising from 1 to 4 carbon atoms.
42. The method of claim 41 wherein said subject is a human.
EP19900902050 1989-01-31 1990-01-16 N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists Withdrawn EP0457773A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30434689A 1989-01-31 1989-01-31
US304346 1989-01-31

Publications (2)

Publication Number Publication Date
EP0457773A1 EP0457773A1 (en) 1991-11-27
EP0457773A4 true EP0457773A4 (en) 1993-03-10

Family

ID=23176133

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900902050 Withdrawn EP0457773A4 (en) 1989-01-31 1990-01-16 N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists

Country Status (4)

Country Link
EP (1) EP0457773A4 (en)
KR (1) KR910700253A (en)
AU (1) AU626983B2 (en)
WO (1) WO1990009178A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0363320A3 (en) * 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituted 9h purine
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
US5256650A (en) * 1989-03-29 1993-10-26 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5391739A (en) * 1989-03-29 1995-02-21 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
GB9125001D0 (en) * 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
ES2196181T3 (en) 1995-11-01 2003-12-16 Novartis Ag PURINE DERIVATIVES AND PROCESS FOR PREPARATION.
WO1997018212A1 (en) * 1995-11-14 1997-05-22 Pharmacia & Upjohn S.P.A. Aryl and heteroaryl purine compounds
US5795756A (en) * 1995-12-11 1998-08-18 Johnson; Roger A. Method and compounds for the inhibition of adenylyl cyclase
AU698419B2 (en) * 1996-07-03 1998-10-29 Dainippon Sumitomo Pharma Co., Ltd. A novel purine derivative
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
GB2378180B8 (en) 2001-06-27 2009-10-21 Cyclacel Ltd New purine derivatives
ITRM20010465A1 (en) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAM
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CA2601032A1 (en) * 2005-03-11 2006-09-21 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof
CZ303054B6 (en) * 2010-09-07 2012-03-14 Univerzita Palackého v Olomouci Use of 6-substituted 9-haloalkyl purines for regulating growth and development of plants, vegetable organs and cells, and novel 6-substituted 9-haloalkyl purines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA657337A (en) * 1963-02-05 D. Zwahlen Kenneth Substituted adenines
NL262940A (en) * 1960-03-31
US3930005A (en) * 1973-06-15 1975-12-30 Squibb & Sons Inc Antiinflammatory agents and their use
DE2355536A1 (en) * 1973-11-07 1975-05-22 Merck Patent Gmbh ADENIN DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4287188A (en) * 1977-02-24 1981-09-01 Burroughs Wellcome Co. Purine derivatives
GB2041359B (en) * 1979-01-10 1982-12-15 Ici Ltd Purine derivatives and their use in the defoliation of cotton plants
JPS606616B2 (en) * 1982-05-27 1985-02-19 隆弘 長崎 Method for producing noodles with fresh yuzu skin
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
DE3529497A1 (en) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N (ARROW HIGH) 6 (ARROW HIGH) -DISUBSTITUTED PURINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 103, no. 3, 22 July 1985, Columbus, Ohio, US; abstract no. 22353q, page 554 ;column 1 ; *
See also references of WO9009178A1 *
TETRAHEDRON vol. 28, no. 3, February 1972, GREAT BRITAIN pages 535 - 547 T. ITAYA ET. AL. 'Purines-6.' *
THE JOURNAL OF ORGANIC CHEMISTRY vol. 48, no. 6, 25 March 1983, pages 850 - 855 NICO J. KOS 'Anion Formation and Ring Opening of 9-Substituted Purines in Liquid Ammonia Containing Potassium Amide.' *

Also Published As

Publication number Publication date
WO1990009178A1 (en) 1990-08-23
KR910700253A (en) 1991-03-14
AU626983B2 (en) 1992-08-13
EP0457773A1 (en) 1991-11-27
AU4941490A (en) 1990-09-05

Similar Documents

Publication Publication Date Title
US5565566A (en) N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
EP0457773A4 (en) N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5117830A (en) Method of determining viability of tissue
Jacobson et al. 1, 3‐Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors
JP2954971B2 (en) Selective adenosine receptor agent
US5256398A (en) Composition for determining viability of tissue
US5047534A (en) Selective adenosine receptor agents
US5066655A (en) N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5256650A (en) Selective adenosine receptor agents
JP3014000B2 (en) Selective adenosine receptor compounds
US5064947A (en) Selective adenosine reseptor compounds
EP0383759B1 (en) N6 substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5734052A (en) 8-substituted xanthines as selective adenosine receptor agents
EP0662975B1 (en) 2-substituted adenosines with a-2 receptor affinity
US5391739A (en) Selective adenosine receptor agents
US5086176A (en) Tricyclic fused adenine derivatives
JPH04503506A (en) N↓6-substituted 9-methyladenine: a new class of adenosine receptor antagonist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910730

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WHITBY RESEARCH, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 19930118

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950510

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950921